Sinsin Pharmaceutical Co. Ltd (002800) - Total Liabilities
Based on the latest financial reports, Sinsin Pharmaceutical Co. Ltd (002800) has total liabilities worth ₩65.10 Billion KRW (≈ $44.12 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002800 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Sinsin Pharmaceutical Co. Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Sinsin Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Sinsin Pharmaceutical Co. Ltd.
Sinsin Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Sinsin Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grazziotin S.A
SA:CGRA3
|
Brazil | R$372.38 Million |
|
Glaston Oyj Abp
HE:GLA1V
|
Finland | €108.60 Million |
|
ENERGY&MACHINERY KOREA Co.Ltd
KQ:095190
|
Korea | ₩125.37 Billion |
|
Kestrel Group, Ltd.
NASDAQ:KG
|
USA | $805.65 Million |
|
Siam Steel Service Center Public Company Limited
BK:SSSC
|
Thailand | ฿463.52 Million |
|
Ekarat Engineering Public Company Limited
BK:AKR
|
Thailand | ฿486.51 Million |
|
Strongpoint ASA
OL:STRO
|
Norway | Nkr529.41 Million |
|
InkTec Co. Ltd
KQ:049550
|
Korea | ₩79.82 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Sinsin Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sinsin Pharmaceutical Co. Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinsin Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinsin Pharmaceutical Co. Ltd (2016–2024)
The table below shows the annual total liabilities of Sinsin Pharmaceutical Co. Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩63.61 Billion ≈ $43.11 Million |
+2.07% |
| 2023-12-31 | ₩62.32 Billion ≈ $42.23 Million |
+1.31% |
| 2022-12-31 | ₩61.52 Billion ≈ $41.69 Million |
+3.59% |
| 2021-12-31 | ₩59.38 Billion ≈ $40.24 Million |
-4.13% |
| 2020-12-31 | ₩61.94 Billion ≈ $41.98 Million |
-15.01% |
| 2019-12-31 | ₩72.87 Billion ≈ $49.39 Million |
+36.52% |
| 2018-12-31 | ₩53.38 Billion ≈ $36.18 Million |
+99.66% |
| 2017-12-31 | ₩26.74 Billion ≈ $18.12 Million |
-22.23% |
| 2016-12-31 | ₩34.38 Billion ≈ $23.30 Million |
-- |
About Sinsin Pharmaceutical Co. Ltd
Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling sheets, bruise treatment creams, and other products. The company also develops transdermal drug delivery … Read more